Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Subscribe To Our Newsletter & Stay Updated
